tbuckley/cabot-search huggingface dataset:
A Bispecific Peptide‐Polymer Conjugate Bridging Target‐Effector Cells to Enhance Immunotherapy
Authors: Wei Zhang, Dongdong Li, Xiaodan Xu, Yong Chen, Xueying Shi, Yixuan Pan, Shasha Yao, Ying Piao, Zhuxian Zhou, Nigel K. H. Slater, Youqing Shen, Jianbin Tang
Journal: Advanced Healthcare Materials (2023)

Peptide-based immune checkpoint inhibitors exhibit remarkable therapeutic benefits although their application is hindered by quick blood clearance and low affinity with receptors. The modification of the peptides into artificial antibodies is an ideal platform to solve these problems, and one of the optional pathways is the conjugation of peptides with a polymer. More importantly, the bridging effect, mediated by bispecific artificial antibodies, could promote the interaction of cancer cells and T cells, which will benefit cancer immunotherapy. Herein, a bispecific peptide-polymer conjugate (octa PEG-PD1-PDL1) is prepared by simultaneously conjugating PD1-binding and PDL1-binding peptides onto 8-arm-PEG. octa PEG-PD1-PDL1 bridges T cells and cancer cells and thus enhances T cell-mediated cytotoxicity against cancer cells. Meanwhile, the tumor-targeting octa PEG-PD1-PDL1 increases the infiltration of cytotoxic T lymphocytes in tumors and reduces their exhaustion. It effectively activates the tumor immune microenvironment and exerts a potent antitumor effect against CT26 tumor models with a tumor inhibition rate of 88.9%. This work provides a novel strategy to enhance tumor immunotherapy through conjugating bispecific peptides onto a hyperbranched polymer to effectively engage target-effector cells.
Photothermal “nano-dot” reactivate “immune-hot” for tumor treatment via reprogramming cancer cells metabolism
Authors: Yang Lu, Yang Wang, Weijian Liu, He Ma, Bo Yang, Kun Shao, Saran Long, Wen Sun, Jianjun Du, Jiangli Fan, Bin Liu, Lei Wang, Xiaojun Peng
Journal: Biomaterials (2023)
In adults with delirium in the ICU, haloperidol did not increase number of days alive out of the hospital at 90 d
Authors: Michael Tanner
Journal: Annals of Internal Medicine (2023)

Andersen-Ranberg NC, Poulsen LM, Perner A, et al. Haloperidol for the treatment of delirium in ICU patients. N Engl J Med. 2022;387:2425-35. 36286254.
In advanced progressive CKD, discontinuing RAS inhibitors did not improve eGFR at 3 y
Authors: Donald Molony, Andrew Horvit, Dia Waguespack
Journal: Annals of Internal Medicine (2023)

ACP Journal ClubMarch 2023In advanced progressive CKD, discontinuing RAS inhibitors did not improve eGFR at 3 yDonald Molony, MD, Andrew Horvit, BS, Dia Waguespack, MDDonald Molony, MDUniversity of Texas Health Science Center at Houston–McGovern Medical School, Houston, Texas, USA (D.M., A.H., D.W.)Search for more papers by this author, Andrew Horvit, BSUniversity of Texas Health Science Center at Houston–McGovern Medical School, Houston, Texas, USA (D.M., A.H., D.W.)Search for more papers by this author, Dia Waguespack, MDUniversity of Texas Health Science Center at Houston–McGovern Medical School, Houston, Texas, USA (D.M., A.H., D.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J23-0001 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationBhandari S, Mehta S, Khwaja A, et al. Renin–angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387:2021-32. https://pubmed.ncbi.nlm.nih.gov/36326117Clinical Impact RatingsGIM/FP/GP: Cardiology: Nephrology: References1. Ahmed A, Kamath N, Kossi M, et al. The impact of stopping inhibitors of the renin–angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010;25:3977-82. [PMID: 19820248] Google Scholar2. Zhang Y, He D, Zhang W, et al. ACE inhibitors benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials. Drugs. 2020;80:797-811. [PMID: 32333236] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Texas Health Science Center at Houston–McGovern Medical School, Houston, Texas, USA (D.M., A.H., D.W.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J23-0001.This article was published at Annals.org on 7 March 2023.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Current IssueMarch 2023Volume 176, Issue 3Page: JC28KeywordsACE inhibitorsBlood pressureChronic kidney diseaseEstimated glomerular filtration rateKidneysMedical dialysisMyocardial infarctionRenal failureRenal transplantation ePublished: 7 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y
Authors: Y. Diana Kwong, Chi-yuan Hsu
Journal: Annals of Internal Medicine (2023)

ACP Journal ClubMarch 2023In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 yY. Diana Kwong, MD, MAS, Chi-yuan Hsu, MD, MScY. Diana Kwong, MD, MASUniversity of California, San Francisco, San Francisco, California, USA (Y.D.K., C.H.)Search for more papers by this author, Chi-yuan Hsu, MD, MScUniversity of California, San Francisco, San Francisco, California, USA (Y.D.K., C.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J23-0009 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationEMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-27. https://pubmed.ncbi.nlm.nih.gov/36331190Clinical Impact RatingsGIM/FP/GP: Cardiology: Nephrology: References1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46. [PMID: 32970396] Google Scholar2. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24. [PMID: 32865377] Google Scholar3. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306. [PMID: 30990260] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of California, San Francisco, San Francisco, California, USA (Y.D.K., C.H.)Disclosures: The commentators have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J23-0009.This article was published at Annals.org on 7 March 2023.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Current IssueMarch 2023Volume 176, Issue 3Page: JC26KeywordsCardiovascular disease riskChronic kidney diseaseEstimated glomerular filtration rateHazard ratioHeartPolycystic kidney diseaseRenal diseasesRenal transplantationSodium-glucose cotransporter-2 inhibitors ePublished: 7 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
In acute HF in the ED, a risk-based management algorithm vs. usual care reduced a composite clinical outcome at 30 d
Authors: Mitchell Levine
Journal: Annals of Internal Medicine (2023)

ACP Journal ClubMarch 2023In acute HF in the ED, a risk-based management algorithm vs. usual care reduced a composite clinical outcome at 30 dMitchell Levine, MDMitchell Levine, MDMcMaster University, Hamilton, Ontario, Canada (M.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J23-0004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationLee DS, Straus SE, Farkouh ME, et al. Trial of an intervention to improve acute heart failure outcomes. N Engl J Med. 2023;388:22-32. https://pubmed.ncbi.nlm.nih.gov/36342109Clinical Impact RatingsEmergency Med: Hospitalists: Cardiology: Author, Article, and Disclosure InformationAuthors: Mitchell Levine, MDAffiliations: McMaster University, Hamilton, Ontario, Canada (M.L.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J23-0004.This article was published at Annals.org on 7 March 2023.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoIn adults with acute HF, high-intensity care vs. usual care reduced a composite of death or HF readmission at 180 d Mitchell Levine Metrics March 2023Volume 176, Issue 3Page: JC31KeywordsAlgorithmsEmergency departmentHeart failureHospitalizationsMortalityOutpatient clinicsRandomized trialsSafetyTreatment guidelines ePublished: 7 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes
Authors: Tejas Patel
Journal: Annals of Internal Medicine (2023)

Source Citation Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788-801. 36351458
In adults with acute HF, high-intensity care vs. usual care reduced a composite of death or HF readmission at 180 d
Authors: Mitchell Levine
Journal: Annals of Internal Medicine (2023)

Source Citation Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400:1938-52. 36356631
In symptomatic AF, cryoballoon ablation reduced progression to persistent AF vs. antiarrhythmic therapy at 3 y
Authors: Nigel S. Tan
Journal: Annals of Internal Medicine (2023)

Andrade JG, Deyell MW, Macle L, et al. Progression of atrial fibrillation after cryoablation or drug therapy. N Engl J Med. 2023;388:105-16. 36342178.
Comparison of Over-the-Scope Clips to Standard Endoscopic Treatment as the Initial Treatment in Patients With Bleeding From a Nonvariceal Upper Gastrointestinal Cause
Authors: James Y.W. Lau, Rui Li, Chen-huan Tan, Xiu-jing Sun, Hao-jun Song, Lan Li, Feng Ji, Bu-jiang Wang, Dong-tao Shi, Wai K. Leung, Imogen Hartley, Alan Moss, Karina Y.Y. Yu, Bing Y. Suen, Peng Li, Francis K.L. Chan
Journal: Annals of Internal Medicine (2023)

Current endoscopic methods in the control of acute nonvariceal bleeding have a small but clinically significant failure rate. The role of over-the-scope clips (OTSCs) as the first treatment has not been defined.To compare OTSCs with standard endoscopic hemostatic treatments in the control of bleeding from nonvariceal upper gastrointestinal causes.A multicenter, randomized controlled trial. (ClinicalTrials.gov: NCT03216395).University teaching hospitals in Hong Kong, China, and Australia.190 adult patients with active bleeding or a nonbleeding visible vessel from a nonvariceal cause on upper gastrointestinal endoscopy.Standard hemostatic treatment (n = 97) or OTSC (n = 93).The primary outcome was 30-day probability of further bleeds. Other outcomes included failure to control bleeding after assigned endoscopic treatment, recurrent bleeding after initial hemostasis, further intervention, blood transfusion, and hospitalization.The 30-day probability of further bleeding in the standard treatment and OTSC groups was 14.6% (14 of 97) and 3.2% (3 of 93), respectively (risk difference, 11.4 percentage points [95% CI, 3.3 to 20.0 percentage points]; P = 0.006). Failure to control bleeding after assigned endoscopic treatment in the standard treatment and OTSC groups was 6 versus 1 (risk difference, 5.1 percentage points [CI, 0.7 to 11.8 percentage points]), respectively, and 30-day recurrent bleeding was 8 versus 2 (risk difference, 6.6 percentage points [CI, -0.3 to 14.4 percentage points]), respectively. The need for further interventions was 8 versus 2, respectively. Thirty-day mortality was 4 versus 2, respectively. In a post hoc analysis with a composite end point of failure to successfully apply assigned treatment and further bleeds, the event rate was 15 of 97 (15.6%) and 6 of 93 (6.5%) in the standard and OTSC groups, respectively (risk difference, 9.1 percentage points [CI, 0.004 to 18.3 percentage points]).Clinicians were not blinded to treatment and the option of crossover treatment.Over-the-scope clips, as an initial treatment, may be better than standard treatment in reducing the risk for further bleeding from nonvariceal upper gastrointestinal causes that are amenable to OTSC placement.General Research Fund to the University Grant Committee, Hong Kong SAR Government.
In adults receiving mechanical ventilation, selective decontamination of the digestive tract reduces hospital mortality
Authors: Naomi P. O’Grady
Journal: Annals of Internal Medicine (2023)

Hammond NE, Myburgh J, Seppelt I, et al. Association between selective decontamination of the digestive tract and in-hospital mortality in intensive care unit patients receiving mechanical ventilation: a systematic review and meta-analysis. JAMA. 2022;328:1922-34. 36286098.
Antihypertensive therapy reduced incident dementia vs. placebo at a median 4.3 y
Authors: Chirag Bavishi
Journal: Annals of Internal Medicine (2023)

Source CitationPeters R, Xu Y, Fitzgerald O, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022;43:4980-90. https://pubmed.ncbi.nlm.nih.gov/36282295/AbstractClinical Impact RatingsGIM/FP/GP: Cardiology: Neurology:
Effect of Prosthesis-Patient Mismatch on Long-Term Clinical Outcomes After Bioprosthetic Aortic Valve Replacement
Authors: Michael Dismorr, Natalie Glaser, Anders Franco-Cereceda, Ulrik Sartipy
Journal: Journal of the American College of Cardiology (2023)

Prosthesis-patient mismatch (PPM) is common following surgical aortic valve replacement (SAVR). The purpose of this study was to quantify the impact of PPM on all-cause mortality, heart failure hospitalization, and reintervention following bioprosthetic SAVR. This observational nationwide cohort study from SWEDEHEART (Swedish Web system for Enhancement and Development of Evidence based care in Heart disease Evaluated According to Recommended Therapies) and other national registers included all patients who underwent primary bioprosthetic SAVR in Sweden from 2003 to 2018. PPM was defined according to the Valve Academic Research Consortium 3 criteria. Outcomes were all-cause mortality, heart failure hospitalization, and aortic valve reintervention. Regression standardization was used to account for intergroup differences and to estimate cumulative incidence differences. We included 16,423 patients (no PPM: 7,377 [45%]; moderate PPM: 8,502 [52%]; and severe PPM: 544 [3%]). After regression standardization, the cumulative incidence of all-cause mortality at 10 years was 43% (95% CI: 24%-44%) in the no PPM group compared with 45% (95% CI: 43%-46%) and 48% (95% CI: 44%-51%) in the moderate and severe PPM groups, respectively. The survival difference at 10 years was 4.6% (95% CI: 0.7%-8.5%) and 1.7% (95% CI: 0.1%-3.3%) in no vs severe PPM and no vs moderate PPM, respectively. The difference in heart failure hospitalization at 10 years was 6.0% (95% CI: 2.2%-9.7%) in severe vs no PPM. There was no difference in aortic valve reintervention in patients with or without PPM. Increasing grades of PPM were associated with long-term mortality, and severe PPM was associated with increased heart failure. Moderate PPM was common, but the clinical significance may be negligible because the absolute risk differences in clinical outcomes were small.
Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction
Authors: Muthiah Vaduganathan, Brian L. Claggett, Pardeep Jhund, Zi Michael Miao, Rudolf A. de Boer, Carolyn S.P. Lam, Akshay S. Desai, Olof Bengsston, John J.V. McMurray, Scott D. Solomon
Journal: Journal of the American College of Cardiology (2023)
Prevalence and Complications of Aberrant Subclavian Artery in Patients With Heritable and Nonheritable Arteriopathies
Authors: Lorenzo Giuliani, Alessandro Di Toro, Mario Urtis, Nupoor Narula, Maurizia Grasso, Stefano Pelenghi, Mirko Belliato, Antonio Bozzani, Vittorio Arici, Carlo Pellegrini, Alessandra Serio, Andrea Pilotto, Viola Fergnani, Elena Antoniazzi, Lorenzo Magrassi, Roberto Dore, Adele Valentini, Lorenzo Preda, Fabrizio Calliada, Pietro Quaretti, Stefano Pirrelli, Takaide Kodama, Luca Vricella, Duke Cameron, Eloisa Arbustini
Journal: Journal of the American College of Cardiology (2023)

An aberrant subclavian artery (ASA) (or lusoria) is the most common congenital anomaly of the aortic arch (0.5%-2.2%; female-to-male ratio 2:1 to 3:1). ASA can become aneurysmal and result in dissection, involving Kommerell's diverticulum when present and the aorta. Data of its significance in genetic arteriopathies are not available. The purpose of this study was to assess the prevalence and complications of ASA in gene-positive and -negative nonatherosclerotic arteriopathies. The series includes 1,418 consecutive patients with gene-positive (n = 854) and gene-negative arteriopathies (n = 564) diagnosed as part of institutional work-up for nonatherosclerotic syndromic and nonsyndromic arteriopathies. Comprehensive evaluation includes genetic counseling, next-generation sequencing multigene testing, cardiovascular and multidisciplinary assessment, and whole-body computed tomography angiography. ASA was found in 34 of 1,418 cases (2.4%), with a similar prevalence in gene-positive (n = 21 of 854, 2.5%) and gene-negative (n = 13 of 564, 2.3%) arteriopathies. Of the former 21 patients, 14 had Marfan syndrome, 5 had Loeys-Dietz syndrome, 1 had type-IV Ehlers-Danlos syndrome, and 1 had periventricular heterotopia type 1. ASA did not segregate with genetic defects. Dissection occurred in 5 of 21 patients with genetic arteriopathies (23.8%; 2 Marfan syndrome and 3 Loeys-Dietz syndrome), all with associated Kommerell's diverticulum. No dissections occurred in gene-negative patients. At baseline, none of the 5 patients with ASA dissection fulfilled criteria for elective repair according to guidelines. The risk of complications of ASA is higher in patients with genetic arteriopathies and is difficult to predict. In these diseases, imaging of the supra-aortic trunks should enter baseline investigations. Determination of precise indications for repair can prevent unexpected acute events such as those described.
Diagnostic and Prognostic Role of Cardiac Magnetic Resonance in MINOCA
Authors: Niya Mileva, Pasquale Paolisso, Emanuele Gallinoro, Davide Fabbricatore, Daniel Munhoz, Luca Bergamaschi, Marta Belmonte, Panayot Panayotov, Carmine Pizzi, Emanuele Barbato, Martin Penicka, Daniele Andreini, Dobrin Vassilev
Journal: JACC. Cardiovascular imaging (2023)
Can Machine Learning Disrupt the Prediction of Sudden Death?
Authors: Sanjiv M. Narayan, Albert J. Rogers
Journal: Journal of the American College of Cardiology (2023)

In patients treated with implantable cardioverter defibrillator (ICD), prediction of both overall survival and occurrence of shocks is important if improved patient selection is desired. We prospectively studied the predictive value of biomarkers and indexes of cardiac and renal function and spectral microvolt T-wave alternans testing and 24-hour Holter variables in a population who underwent first ICD implantation. Consecutive patients in sinus rhythm with ischemic or dilated cardiomyopathy scheduled for primary or secondary prophylactic ICD implantation were enrolled. Exercise microvolt T-wave alternans and 24-hour Holter for number of ventricular premature contractions (VPCs), deceleration capacity, heart rate variability, and heart rate turbulence were done. Death of any cause and first appropriate ICD shock were defined as end points. Over 33 ± 15 months of follow-up, 36 of 253 patients (14%) received appropriate shocks and 39 of 253 patients (15%) died. Only 3 of 253 patients (1%) died after receiving at least 1 appropriate shock. In univariate analyses, New York Heart Association class, ejection fraction, N-terminal pro brain-type natriuretic peptide (NT-proBNP), renal function, ICD indication, deceleration capacity, heart rate variability, and heart rate turbulence were predictive of all-cause mortality and VPC number and deceleration capacity predicted first appropriate shock. NT-proBNP (≥1,600 pg/ml) was identified as the only independent predictor of all-cause mortality (hazard ratio 3.0, confidence interval 1.3 to 7.3, p = 0.014). In contrast, VPC number predicted appropriate shocks (hazard ratio 2.3, confidence interval 1.0 to 5.5, p = 0.047) as the only independent risk marker. In conclusion, NT-proBNP is a strong independent predictor of mortality in a typical prospective cohort of newly implanted patients with ICD, among many electrocardiographic and clinical variables studied. Number of VPCs was identified as a predictor of appropriate shocks (clinicaltrials.gov: NCT02010515).
Sex Differences in Epidemiology, Care, and Outcomes in Patients With Acute Chest Pain
Authors: Luke P. Dawson, Emily Nehme, Ziad Nehme, Esther Davis, Jason Bloom, Shelley Cox, Adam J. Nelson, Daniel Okyere, David Anderson, Michael Stephenson, Jeffrey Lefkovits, Andrew J. Taylor, Stephen J. Nicholls, Louise Cullen, David Kaye, Karen Smith, Dion Stub
Journal: Journal of the American College of Cardiology (2023)
Diagnostic Accuracy of CMR With Late Gadolinium Enhancement for Ischemic Cardiomyopathy
Authors: Christos A. Papanastasiou, Polydoros N. Kampaktsis, Maria-Anna Bazmpani, Thomas Zegkos, Georgios Efthimiadis, Apostolos Tsapas, Antonios Ziakas, Theodoros D. Karamitsos
Journal: JACC. Cardiovascular imaging (2023)
Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization
Authors: Ankeet S. Bhatt, Anubodh S. Varshney, Alea Moscone, Brian L. Claggett, Zi Michael Miao, Safia Chatur, Mathew S. Lopes, John W. Ostrominski, Maria A. Pabon, Ozan Unlu, Xiaowen Wang, Thomas D. Bernier, Leo F. Buckley, Bryan Cook, Rachael Eaton, Jillian Fiene, Dareen Kanaan, Julie Kelly, Danielle M. Knowles, Kenneth Lupi, Lina S. Matta, Liriany Y. Pimentel, Megan N. Rhoten, Rhynn Malloy, Clara Ting, Rosette Chhor, Joshua R. Guerin, Scott L. Schissel, Brenda Hoa, Connie H. Lio, Kristina Milewski, Michelle E. Espinosa, Zhenzhen Liu, Ralph McHatton, Jonathan W. Cunningham, Karola S. Jering, John H. Bertot, Gurleen Kaur, Adeel Ahmad, Muhammad Akash, Farideh Davoudi, Mona Z. Hinrichsen, David L. Rabin, Patrick L. Gordan, David J. Roberts, Daniela Urma, Erin E. McElrath, Emily D. Hinchey, Niteesh K. Choudhry, Mahan Nekoui, Scott D. Solomon, Dale S. Adler, Muthiah Vaduganathan
Journal: Journal of the American College of Cardiology (2023)
Risk of Incident Thromboembolic and Ischemic Events After COVID-19 Vaccination Compared With SARS-CoV-2 Infection
Authors: Mats C. Højbjerg Lassen, Daniel Modin, Kristoffer Grundtvig Skaarup, Niklas Dyrby Johansen, Brian Claggett, Scott D. Solomon, Michael Fralick, Jens Ulrik Stæhr Jensen, Pradeesh Sivapalan, Muthiah Vaduganathan, Manan Pareek, Morten Schou, Tyra Grove Krause, Anders Hviid, Lars Køber, Christian Torp-Pedersen, Gunnar Gislason, Tor Biering-Sørensen
Journal: Circulation (2023)